Apremilast is approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet’s disease. It is also approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis in several other countries.
The recommended dosage of apremilast varies depending on the specific condition being treated, as well as the patient’s age, weight, and other factors. Common side effects of apremilast include diarrhea, nausea, headache, and upper respiratory tract infection.
